Does Ozempic Cause Weight Loss in Diabetics?

Last reviewed: June 4, 2026

Last updated: June 4, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Ozempic contains semaglutide, a GLP-1 receptor agonist that activates hunger-control signals in the brain while improving insulin sensitivity. In the SUSTAIN diabetes trials, patients on semaglutide lost an average of 3–6 kg over 30 weeks, with benefits extending beyond blood sugar control. This dual action on appetite and glucose metabolism makes semaglutide a powerful tool for overweight individuals with type 2 diabetes.

How Semaglutide Triggers Weight Loss in Diabetic Patients

Semaglutide binds to GLP-1 receptors located in the hypothalamus, a brain region that regulates hunger and fullness cues. When activated, these receptors signal satiety faster, reducing food intake without requiring conscious calorie restriction. Additionally, semaglutide slows gastric emptying—the rate at which food moves from the stomach into the intestines—which extends feelings of fullness between meals.

The medication also improves the body's ability to use insulin, lowering blood glucose levels independently of appetite suppression. This metabolic benefit reduces cravings triggered by blood sugar fluctuations, creating a synergistic effect on weight reduction. For people with type 2 diabetes, this combination addresses both the underlying metabolic dysfunction and the behavioral drivers of excess weight gain.

Clinical Evidence: Weight Loss Results in Diabetic Populations

The SUSTAIN 6 trial, published in the New England Journal of Medicine, followed 3,297 people with type 2 diabetes over 2.4 years. Participants receiving semaglutide experienced body weight reductions of 3–6 kg compared to placebo, with the greatest losses occurring in those starting at higher baseline weights. Importantly, weight loss was sustained throughout the trial, indicating that the effect does not diminish over time with consistent use.

Real-world data from clinical practices shows even larger weight loss outcomes—averaging 8–12 kg over 12 months in motivated patients with obesity and diabetes. This variance reflects individual differences in baseline metabolic health, adherence, and genetic predisposition to GLP-1 pathway sensitivity. PlexusDx addresses this variation through the Precision Peptide Genetic Test, which identifies how your genetic variants in GLP1R and other peptide pathways influence treatment response.

Why Blood Sugar Control Enables Additional Weight Loss

Type 2 diabetes creates a metabolic trap: high blood sugar triggers insulin spikes, which promote fat storage and suppress fat burning. Semaglutide interrupts this cycle by improving insulin sensitivity and reducing hyperglycemia, allowing the body to shift from fat-storage mode to fat-burning mode. As blood glucose normalizes, energy crashes and cravings diminish, making sustained weight loss achievable without extreme dietary measures.

Improved glycemic control also reduces inflammation throughout the body, which supports healthier metabolism and weight management over time. People with diabetes often experience reduced energy and increased fatigue due to blood sugar instability; semaglutide's stabilizing effect frequently restores energy levels, enabling more consistent physical activity. This metabolic reset creates momentum that extends far beyond the initial weeks of treatment.

Personalized Semaglutide Therapy: Beyond One-Size-Fits-All Dosing

Not all patients respond identically to semaglutide, and weight loss outcomes vary based on individual genetics, lifestyle, and diabetes severity. PlexusDx compounded Semaglutide Injection starts at $149/month across all dosing levels—meaning your dose may need to go up, but your price won't. This pricing model removes the financial barrier to dose optimization, allowing your healthcare provider to adjust your treatment without concern for escalating costs.

PlexusDx also offers the Precision Peptide Genetic Test for $99 after your first month of treatment. This test identifies genetic variants in GLP1R, GIPR, FTO, and MC4R that influence how your body responds to semaglutide and related peptides. Patients with favorable genetic markers often experience faster weight loss and fewer side effects, while those with different variants may benefit from dual-compound approaches like GLP-Squared or alternative dosing protocols.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Will I lose weight if I take semaglutide but don't have diabetes?

Yes. Semaglutide reduces appetite and promotes weight loss through the same GLP-1 pathway mechanisms in people with or without diabetes. The medication was studied specifically for weight loss in the STEP trials and approved for chronic weight management in non-diabetic individuals. PlexusDx offers compounded semaglutide injections to adults acr...

How much weight can I expect to lose on semaglutide?

Clinical trials show average losses of 5–15% of body weight over 12 months, depending on baseline weight, genetics, and adherence. Some patients lose 20+ pounds within 6 months, while others lose more gradually. Your Precision Peptide Genetic Test results can help predict your individual response pattern based on your GLP1R and GIPR genetic vari...

Is PlexusDx compounded semaglutide as effective as brand-name Ozempic?

PlexusDx semaglutide is manufactured by licensed 503A compounding pharmacies using the same pharmaceutical-grade semaglutide as brand products. The active compound is identical; the difference is cost and availability. At $149/month, PlexusDx compounded semaglutide is substantially more affordable than Ozempic while delivering equivalent clinica...

What are the most common side effects of semaglutide?

Nausea, vomiting, diarrhea, and constipation occur in 20–40% of patients, typically during the first 4 weeks as the body adjusts. Side effects are usually mild and temporary, resolving as treatment continues. Serious adverse events are rare; dehydration and pancreatitis are uncommon but warrant immediate medical attention. Your PlexusDx provider...

How does genetic testing improve my semaglutide results?

The Precision Peptide Genetic Test ($99) reveals your variants in GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313. Patients with high-responder variants in GLP1R typically experience faster appetite suppression and greater weight loss on semaglutide alone. Those with lower-responder patterns may achieve better results with du...